Biomarker Core

生物标志物核心

• 批准号: 10187490
• 负责人: ADAM M BRICKMAN
• 金额: $ 34.52万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10187490
• 关键词: APLP1 gene; Alzheimer' s Disease; Alzheimer’s disease biomarker; Amyloid; Apolipoproteins; Biological; Biological Markers; Blood; Brain; Cerebrospinal Fluid; Cerebrovascular Disorders; Cholesterol Homeostasis; Classification Scheme; Clinical; Cognitive aging; Communities; Data; Data Sources; Data Store; Databases; Dementia; Detection; Development; Diagnostic; Disease; Enrollment; Etiology; Goals; Heterogeneity; Human; Immune response; Immunologic Markers; Infarction; Information Systems; Infrastructure; International; Light; Liquid substance; MRI Scans; Magnetic Resonance Imaging; Measurement; Methods; Molecular; Nerve Degeneration; Participant; Pathway interactions; Plasma; Positron-Emission Tomography; Process; Protocols documentation; Radiology Specialty; Research; Research Personnel; Research Proposals; Resources; Scanning; Scientist; Secure; Sensitivity and Specificity; Standardization; Stream; Technology; Thick; Universities; White Matter Hyperintensity; Work; base; cerebrovascular; data exchange; exosome; imaging biomarker; improved; in vivo; instrumentation; interest; magnetic resonance imaging biomarker; neurofilament; neuroimaging; neuroimaging marker; next generation; novel; novel marker; potential biomarker; programs; single molecule; sulfated glycoprotein 2; tau Proteins; trafficking; training opportunity

BIOMARKER CORE PROJECT SUMMARY/ABSTRACT The ability to study Alzheimer’s disease (AD) and related disorders has been revolutionized by the development and application of in vivo biomarkers. Analysis of cerebrospinal fluid (CSF), positron emission tomography (PET), and magnetic resonance imaging (MRI) allow operational measurement of amyloid, tau, and neurodegeneration (A/T/N), the major pathophysiological changes that define AD. Moreover, improved sensitivity and specificity of instrumentation applied to biofluid data, of neuroimaging protocols, and of analytic approaches both enable and necessitate the development, refinement, and discovery of novel biomarkers in any comprehensive AD research program. The Columbia University ADRC Biomarker Core embraces these theme and will derive standard biofluid and MRI biomarkers for all ADRC participants; serve as a central hub for human biofluid, PET, and MRI-based biomarker research conducted within the cognitive aging and dementia community at Columbia University; develop and implement novel biomarkers; and provide training opportunities for investigators interested in incorporating AD-related biomarkers into their research. The Biomarker Core leverages unique data sources, infrastructural, and intellectual strengths already in place and comprises a team of close-collaborating investigators instrumental to the majority of ongoing AD biomarker studies at Columbia University. The Biomarker Core will analyze research grade MRI scans acquired from harmonized clinical scans, from ongoing studies, or de novo for neurodegenerative and cerebrovascular markers. The Core features a newly-acquired single molecule array (Simoa) Benchtop Multiplexed Biomarker Detection Analyzer and Mesoscale Discovery (MSD) platform for analysis of CSF and blood and development of novel biomarkers. These resources will be used to derive existing blood- and CSF-based biomarkers and to develop novel ones. The deep biomarker characterization of all ADRC participants and close interaction with the other Cores will increase understanding of disease etiology and heterogeneity. The Biomarker Core has the following aims: 1) To harmonize, bank, and disseminate fluid and neuroimaging biomarker data derived from participants enrolled by the Clinical Core; 2) To quantitate biofluid biomarkers and MRI markers of neurodegeneration and cerebrovascular disease, according to the A/T/N classification scheme; 3) To develop, optimize, and implement biomarkers of the three thematic biological pathways: immune response, cholesterol metabolism, and endosomal trafficking; 4) To provide intellectual, analytic, and infrastructural support to local investigators interested in incorporating blood-based, CSF, MRI, and PET imaging biomarkers into their Alzheimer’s-related research programs; and 5) To provide training and training opportunities for the next generation of diverse scientists interested in incorporating biomarkers into the study of cognitive aging and dementia.

BioMarker核心项目摘要/摘要 研究阿尔茨海默病(AD)和相关疾病的能力随着这一发展而发生了革命性的变化 以及体内生物标记物的应用。脑脊液分析、正电子发射断层扫描 (PET)和磁共振成像(MRI)允许操作测量淀粉样蛋白、tau和 神经退行性变(A/T/N)，定义AD的主要病理生理变化。此外，改进了 生物流体数据、神经成像方案和分析仪器的灵敏度和特异度 方法使开发、提炼和发现新的生物标记物成为可能，也是必要的 全面的AD研究计划。哥伦比亚大学ADRC Biomarker Core采用了这些主题 并将为所有ADRC参与者派生标准生物流体和MRI生物标记物；作为人类 在认知老化和痴呆症社区内进行的基于生物流体、PET和MRI的生物标记物研究 在哥伦比亚大学；开发和实施新的生物标志物；并为以下方面提供培训机会 有兴趣将AD相关生物标记物纳入他们的研究的研究人员。 Biomarker Core利用已有的独特数据源、基础架构和智力优势 并由一组密切合作的调查人员组成，这些调查人员对大多数正在进行的AD生物标志物起到了重要作用 在哥伦比亚大学学习。Biomarker Core将分析从以下公司获得的研究级MRI扫描 来自正在进行的研究的统一临床扫描，或神经退行性疾病和脑血管疾病的从头开始 记号笔。Core采用了新收购的单分子阵列(SIMOA)台式多路生物标记物 脑脊液和血液检测分析仪和中尺度发现(MSD)平台及其发展 新的生物标记物。这些资源将用于提取现有的基于血液和脑脊液的生物标记物，并 开发新的产品。所有ADRC参与者的深层生物标志物特征以及与ADRC的密切互动 其他核心将增加对疾病病因和异质性的理解。Biomarker Core拥有 以下目标：1)协调、存储和传播源自以下来源的液体和神经成像生物标志物数据 由临床核心登记的参与者；2)量化生物流体生物标记物和MRI标记物 神经退行性变和脑血管疾病，按A/T/N分类方案；3)发展， 优化并实施免疫应答、胆固醇三条主题性生物途径的生物标记物 新陈代谢和内体贩运；4)向当地提供智力、分析和基础设施支持 有兴趣将血液、脑脊液、核磁共振和PET成像生物标记物纳入他们的 与阿尔茨海默氏症相关的研究计划；以及5)为下一代提供培训和培训机会 一代不同的科学家对将生物标记物纳入认知衰老和 痴呆症。